ESC 2026: Evolocumab explores new frontiers in CV disease prevention - Pharmaceutical Technology

The benefits of intensive LDL-C lowering with Repatha (evolocumab) may extend beyond cardiovascular event prevention to reducing mortality. The benefits of intensive LDL-C lowering with Repatha (evolocumab) may extend beyond cardiovascular event prevention to reducing mortality. In the VESALIUS-CV trial, Amgen’s Repatha (evolocumab) significantly reduced all-cause mortality compared with placebo, with reductions observed in both cardiovascular and non-cardiovascular death. Image credit: [Donenko Oleksii]/Shutterstock.com Unlock FREE Access to Premium Content ​Discover exclusive forecasts, analyst insights, and in-depth pharmaceutical industry analysis spanning drug development, manufacturing, regulation, and global healthcare trends. With a free Pharmaceutical Technology profile, you can: The leading site for…

Source: Pharmaceutical Technology